Use of specified tcf target genes to identify drugs for the treatment of cancer in particular colorectal cancer in which tcf/ss-cateini/wnt signalling plays a central role

F. Colland (Inventor), N. Barker (Inventor), J.C. Clevers (Inventor), E. Gomez (Inventor), M. Lambertus (Inventor), E.S. Suils (Inventor)

Research output: Patent

Abstract

The present invention relates to the use of inhibitors of the expressed proteins of TCF target genes whose expression is regulated by TCF/.beta.-catenin complexes for the preparation of a therapeutical composition for the treatment of cancers in which TCF/.beta.-catenin signalling is deregulated. Such inhibitors can be antibodies, small molecules, antisense RNA and dsRNA for use in RNAi. The invention also relates to these inhibitors per se.
Original languageEnglish
Publication statusPublished - 2006

Bibliographical note

United States Patent 20060165699; http://www.freepatentsonline.com/20060165699.html

Fingerprint Dive into the research topics of 'Use of specified tcf target genes to identify drugs for the treatment of cancer in particular colorectal cancer in which tcf/ss-cateini/wnt signalling plays a central role'. Together they form a unique fingerprint.

  • Cite this